CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 201–300 of 1,001
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 72
(2024) · doi:10.1007/s00395-024-01074-w · Cited by 59
Tao, X., Zhang, R., Du, R., Yu, T., Yang, H., Li, J., Wang, Y., Liu, Q., Zuo, S., Wang, X., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212414 · Cited by 65
Fibroblasts orchestrate cellular crosstalk in the heart through the ECM
Bowers, S., Meng, Q., & Molkentin, J. D. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00043-7 · Cited by 65
Jie, J., Mao, D., Cao, J., Feng, P.-F., & Yang, P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c10727 · Cited by 63
Renal Fibrosis in Lupus Nephritis
Sciascia, S., Cozzi, M., Barinotti, A., Radin, M., Cecchi, I., Fenoglio, R., Mancardi, D., Jones, G. W., Rossi, D., & Roccatello, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214317 · Cited by 62
Optimizing the manufacturing and antitumour response of CAR T therapy
Liu, Y., Sperling, A. S., Smith, E. L., & Mooney, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00031-x · Cited by 63
Chao, C.-J., Zhang, E., & Zhao, Z. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114840 · Cited by 64
Zhang, Z., Ma, B., Li, B., Li, Z., Gao, M., Zhao, H., Peng, R., Hu, J., Wang, Y., You, W., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102209 · Cited by 94
Peikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 74
Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery
Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 61
Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets
Xia, Y., Gao, D., Wang, X., Liu, B., Shan, X., Sun, Y., & Ma, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331609 · Cited by 62
Tilsed, C. M., Sadiq, B. A., Papp, T. E., Areesawangkit, P., Kimura, K., Noguera-Ortega, E., Scholler, J., Cerda, N., Aghajanian, H. K., Bot, A. I., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319856121 · Cited by 60
Self-citationEngineering cells for therapy and diagnosis
Li, Z., Wang, Y., Gu, Z., & Hu, Q. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00198-x · Cited by 60
Yamada, Y., Sadahiro, T., Nakano, K., Honda, S., Abe, Y., Akiyama, T., Fujita, R., Nakamura, M., Maeda, T., Kuze, Y., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067504 · Cited by 58
T cells in cardiac health and disease
Martín, P., & Sánchez‐Madrid, F. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185218 · Cited by 65
CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery
Papp, T. E., Zeng, J., Shahnawaz, H., Akyianu, A., Breda, L., Yadegari, A., Steward, J., Shi, R., Li, Q., Mui, B. L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.018 · Cited by 64
Self-citationTechnological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 68
CTLA-4 tail fusion enhances CAR-T antitumor immunity
Zhou, X., Cao, H., Fang, S., Chow, R. D.-W., Tang, K., Majety, M., Bai, M., Dong, M. B., Renauer, P. A., Shang, X., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01571-5 · Cited by 62
Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering
Mukalel, A. J., Hamilton, A. G., Billingsley, M. M., Li, J. J., Thatte, A. S., Han, X., Safford, H. C., Padilla, M. S., Papp, T. E., Parhiz, H., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312038 · Cited by 63
Self-citationLi, Y., Tian, Y., Li, C., Fang, W., Li, X., Jing, Z., Yang, Z., Zhang, X., Huang, Y., Gong, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102518 · Cited by 61
Liu, Y., Liu, Q., Zhang, B., Chen, S., Shen, Y., Li, Z., Zhang, J., Yang, Y., Li, M., & Wang, Y. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01373-0 · Cited by 66
An, N., Wang, D., Zhang, P., Zhang, J., Parone, P. A., Hu, J., Bao, Y., Xu, L., Ruan, H., Wan, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04244-6 · Cited by 73
Advances in mRNA-Based Cancer Vaccines
Ni, L. (2023) · Vaccines · doi:10.3390/vaccines11101599 · Cited by 61
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 62
Dou, Y., Chen, R., Liu, S., Lee, Y., Ji, J., Liu, X., Ke, Y., Wang, R., Zhou, Y., & Huang, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41164-2 · Cited by 61
Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies
Nele, V., Campani, V., Moosavian, S. A., & Rosa, G. D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115291 · Cited by 63
In vivo site-specific engineering to reprogram T cells
Nyberg, W. A., Bernard, P.-L., Ngo, W., Wang, C. H., Ark, J., Rothrock, A., Borgo, G. M., Kimmerly, G. R., Jung, J. H., Allain, V., et al. (2026) · Nature · doi:10.1038/s41586-026-10235-x · Cited by 70
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 72
Sun, J., Wang, L., Matthews, R. C., Walcott, G. P., Lu, Y., Wei, Y., Zhou, Y., Zangi, L., & Zhang, J. J. (2023) · Circulation Research · doi:10.1161/circresaha.123.322929 · Cited by 59
Steering the course of CAR T cell therapy with lipid nanoparticles
Khawar, M. B., Afzal, A., Si, Y., & Sun, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02630-1 · Cited by 56
Meng, Z., Rodriguez-Ehrenfried, A., Tan, C. L., Steffens, L. K., Kehm, H., Zens, S., Lauenstein, C., Paul, A., Schwab, M., Förster, J. D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh9562 · Cited by 58
Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics
Gil-Cabrerizo, P., Simón‐Yarza, T., Garbayo, E., & Blanco‐Prieto, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115302 · Cited by 58
Ke, B.-J., Abdurahiman, S., Biscu, F., Zanella, G., Dragoni, G., Santhosh, S., Simone, V. D., Zouzaf, A., van Baarle, L., Stakenborg, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173835 · Cited by 59
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins
Eweje, F., Ibrahim, V., Shajii, A., Walsh, M. L., Ahmad, K., Alrefai, A., Miyasato, D. L., Davis, J. R., Ham, H. O., Li, K., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02664-2 · Cited by 66
Application of Biomimetic Cell Membrane-Coated Nanocarriers in Cardiovascular Diseases
Zhao, X., Chen, W., Wu, J., Shen, Y., Xu, B., Chen, Z., & Sun, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s531558 · Cited by 60
Gene Therapy Strategies Targeting Aging-Related Diseases
Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 70
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 56
Nucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting
Wang, Y., Lin, L., Wang, X., Li, J., Pan, Q., Kou, H., Yin, J., Gao, F., Liao, X., Zhang, C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102250 · Cited by 77
Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease
Zhao, S., Li, R., Yuan, X., Wang, X., Liu, Z., Chu, Q., He, J., Zhang, J., Guo, Y., Wang, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.014 · Cited by 60
Guerriaud, M., & Kohli, É. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1012497 · Cited by 53
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Chimeric antigen receptor macrophages target and resorb amyloid plaques
Kim, A. B., Xiao, Q., Yan, P., Pan, Q., Pandey, G., Grathwohl, S., Gonzales, E. R., Xu, I., Cho, Y., Haecker, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175015 · Cited by 55
Li, W., Zhu, X., Xu, Y., Chen, J., Zhang, H., Yang, Z., Qi, Y., Hong, J., Li, Y., Wang, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052717 · Cited by 53
Biomaterials-Mediated Engineering of the Immune System
Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 55
TGF-βR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue
Zhao, G., Xue, L., Weiner, A. I., Gong, N., Adams‐Tzivelekidis, S., Wong, J., Gentile, M. E., Nottingham, A. N., Basil, M. C., Lin, S. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg6229 · Cited by 55
Self-citationCAR-T therapy dilemma and innovative design strategies for next generation
Wang, Z., Li, P., Zeng, X., Guo, J., Zhang, C., Fan, Z., Wang, Z., Zhu, P., & Chen, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07454-x · Cited by 57
Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review
Morva, A., Arroyo, A. B., Andreeva, L., Tapia‐Abellán, A., & Luengo‐Gil, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615760 · Cited by 53
Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases
Jiao, L., Sun, Z., Sun, Z., Liu, J., Deng, G., & Wang, X. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1349077 · Cited by 51
Lipid nanoparticle‐mediated RNA delivery for immune cell modulation
Kim, E. H., Teerdhala, S. V., Padilla, M. S., Joseph, R. A., Li, J. J., Haley, R. M., & Mitchell, M. J. (2024) · European Journal of Immunology · doi:10.1002/eji.202451008 · Cited by 52
Synthetic Biology‐Based Engineering Cells for Drug Delivery
Yi, W., Hu, S., Qian, X., Yan, W., & Li, Y. (2025) · Exploration · doi:10.1002/exp.20240095 · Cited by 67
Hypertension and left ventricular hypertrophy
Djordjevic, D. B., Koracevic, G. P., Đorđević, A. D., & Lović, D. B. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003774 · Cited by 50
Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma
Zhou, L., Li, Y., Zheng, D., Zheng, Y., Cui, Y., Qin, L., Tang, Z., Peng, D., Wu, Q., Long, Y., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200817 · Cited by 63
Park, W., Choi, J., Hwang, J., Kim, S. H., Kim, Y., Shim, M. K., Park, W., Yu, S., Jung, S., Yang, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16562 · Cited by 52
CAR Macrophages Engineered In Vivo for Attenuating Myocardial Ischemia-Reperfusion Injury
Du, H., You, X., Zhang, J., Liu, S., Zhou, Y., Wang, Y., Yang, C., Meng, Y., Liu, X., Zhang, H., et al. (2025) · Circulation Research · doi:10.1161/circresaha.125.326716 · Cited by 49
In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies
Li, C. L., Georgakopoulou, A., Newby, G. A., Everette, K. A., Nizamis, E., Paschoudi, K., Vlachaki, E., Gil, S., Anderson, A. K., Koob, T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.162939 · Cited by 49
Current strategies employed in the manipulation of gene expression for clinical purposes
Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 53
Lipid nanomaterials-based RNA therapy and cancer treatment
Zhang, X., Hai, L., Gao, Y., Yu, G., & Sun, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.004 · Cited by 47
Protein-based nanoparticles for therapeutic nucleic acid delivery
Eweje, F., Walsh, M. L., Ahmad, K., Ibrahim, V., Alrefai, A., Chen, J., & Chaikof, E. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122464 · Cited by 47
Yashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R. B., Chen, L., Lightstone, A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx0368 · Cited by 52
Self-citationTrinh, V. Q.-H., Lee, T.-F., Lemoinne, S., Ray, K. C., Ybanez, M. D., Tsuchida, T., Carter, J. K., Agudo, J., Brown, B. D., Akat, K. M., et al. (2023) · Science Signaling · doi:10.1126/scisignal.adf6696 · Cited by 45
Bressler, E. M., Adams, S. C., Liu, R., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1244 · Cited by 46
The heterocellular heart: identities, interactions, and implications for cardiology
Lother, A., & Köhl, P. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-01000-6 · Cited by 52
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
Schoutrop, E., Renken, S., Nilsson, I. M., Hahn, P., Poiret, T., Kiessling, R. W., Wickström, S. L., Mattsson, J., & Magalhaes, I. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093426 · Cited by 44
RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
Schaible, P., Bethge, W. A., Lengerke, C., & Haraszti, R. Á. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2155 · Cited by 44
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 52
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 45
Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers
Dietmair, B., Humphries, J., Mercer, T. R., Thurecht, K. J., Howard, C. B., & Cheetham, S. W. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102520 · Cited by 51
Xiao, Y., Zhu, T., Chen, Z., & Huang, X. (2025) · Nature Communications · doi:10.1038/s41467-025-62506-2 · Cited by 57
Cellular Heterogeneity of the Heart
Michel, N. A., Ljubojević-Holzer, S., Bugger, H., & Zirlik, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.868466 · Cited by 42
Xie, S., Chen, M., Fang, W., Liu, S., Wu, Q., Liu, C., Xing, Y., Shi, W., Xu, M., Zhang, M., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104359 · Cited by 43
Circular RNAs in Cardiovascular Diseases: Regulation and Therapeutic Applications
Wang, L., Xu, G.-E., Spanos, M., Li, G., Lei, Z., Sluijter, J. P. G., & Xiao, J. (2023) · Research · doi:10.34133/research.0038 · Cited by 54
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Shin, S., Lee, P., Han, J., Kim, S.-N., Lim, J., Park, D.-H., Paik, T., Min, J., Park, C. G., & Park, W. (2023) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-022-00515-8 · Cited by 43
Complex regulation of cardiac fibrosis: insights from immune cells and signaling pathways
Rao, W., Li, D., Zhang, Q., Liu, T., Gu, Z., Huang, L., Dai, J., Wang, J., & Hou, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06260-5 · Cited by 45
Rational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 56
Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles
Lee, D. S., Amirthalingam, S., Lee, C., Rajendran, A. K., Ahn, Y.-H., & Hwang, N. S.-Y. (2023) · Nanoscale Advances · doi:10.1039/d3na00198a · Cited by 40
Li, Z., Amaya, L., Ee, A., Wang, S. K., Ranjan, A., Waymouth, R. M., Chang, H. Y., & Wender, P. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02704 · Cited by 41
Qin, H., Zhou, Z., Shi, R., Mai, Y., Xu, Y., Fu, P., Cheng, G., Zhang, Z., Chen, W., Chen, Y., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01701-6 · Cited by 48
Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy
Hu, Q., Zhao, H., Zhou, K., Tian, X., Wang, Q. Z., Hua, X., & Zhang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02512-4 · Cited by 45
Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis
Shao, J., Liu, J., & Zuo, S. (2022) · Cells · doi:10.3390/cells11152347 · Cited by 42
Current status and perspectives of regulatory T cell-based therapy
Qu, G., Chen, J., Li, Y., Yuan, Y., Liang, R., & Li, B. (2022) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2022.05.005 · Cited by 44
Cell-based intelligent micro/nanorobots for precise regulation and active biotherapy
Huang, G., Yin, T., Zhang, B., Ma, A.-Q., Kang, T., He, Y., Long, Y., Zheng, S., Pan, H., & Cai, L. (2023) · Matter · doi:10.1016/j.matt.2023.09.013 · Cited by 41
Natural killer cell–based immunotherapy for cancer
Ma, S., Yu, J., & Caligiuri, M. A. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf036 · Cited by 47
Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level
Kang, D. D., Marks, A. R., Morlà‐Folch, J., Dong, Y., Brown, B. D., & Teunissen, A. J. P. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01511-8 · Cited by 51
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 58
An mRNA vaccine elicits STING-dependent antitumor immune responses
Chen, Z., Meng, C., Mai, J., Liu, Y., Li, H., & Shen, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.013 · Cited by 42
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Saetzler, V., Riët, T., Schienke, A., Henschel, P., Freitag, K., Haake, A. F. H., Heppner, F. L., Buitrago‐Molina, L. E., Noyan, F., Jaeckel, E., et al. (2023) · Cells · doi:10.3390/cells12162115 · Cited by 43
ROS-responsive drug-releasing injectable microgels for ameliorating myocardial infarction
Wang, S., Yao, Y., Song, L., Zhai, Z., Li, S., Wang, Z., Shen, L., Zhu, Y., Liu, W., & Gao, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122534 · Cited by 39
Hydrophobic mismatch drives self-organization of designer proteins into synthetic membranes
Peruzzi, J. A., Steinkühler, J., Vu, T. Q., Gunnels, T. F., Hu, V. T., Lu, P., Baker, D. A., & Kamat, N. P. (2024) · Nature Communications · doi:10.1038/s41467-024-47163-1 · Cited by 40
Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis
Yang, B., Qiao, Y., Dong, Y., & Meng, Q. (2024) · Cells · doi:10.3390/cells13090764 · Cited by 42
Pluripotent Stem Cells in Clinical Setting—New Developments and Overview of Current Status
Ilić, D., & Ogilvie, C. M. (2022) · Stem Cells · doi:10.1093/stmcls/sxac040 · Cited by 42
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Műzes, G., & Sípos, F. (2023) · Cells · doi:10.3390/cells12111534 · Cited by 42
Mechanical forces amplify TCR mechanotransduction in T cell activation and function
Jeffreys, N. C., Brockman, J. M., Zhai, Y., Ingber, D. E., & Mooney, D. J. (2024) · Applied Physics Reviews · doi:10.1063/5.0166848 · Cited by 43
Targeting cardiac fibrosis with chimeric antigen receptor macrophages
Gao, Z., Yan, L., Meng, J., Lu, Z., Ge, K., Jiang, Z., Feng, T., Wang, H., Liu, C., Tang, J., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00718-4 · Cited by 40
Vaccination-based immunotherapy to target profibrotic cells in liver and lung
Sobecki, M., Chen, J., Krzywińska, E., Nagarajan, S., Fan, Z., Nelius, E., Rodríguez, J. M. M., Seehusen, F., Hussein, A., Moschini, G., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.08.012 · Cited by 42
Xu, X., Hua, X., Han, M., Hu, S., & Song, J. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-022-00972-1 · Cited by 42
Cardiac radiation improves ventricular function in mice and humans with cardiomyopathy
Pedersen, L. N., Ripoll, C. V., Özcan, M., Guo, Z., Lotfinaghsh, A., Zhang, S., Ng, S., Weinheimer, C. J., Nigro, J. M., Kovács, A. D., et al. (2023) · Med · doi:10.1016/j.medj.2023.10.006 · Cited by 40
Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy
Maia, A., Tarannum, M., & Romee, R. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad087 · Cited by 39
Di, X., Chen, J., Li, Y., Wang, M., Wei, J., Li, T., Liao, B., & Luo, D. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1545 · Cited by 46
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.